OBJECTIVE: To evaluate C-reactive protein (CRP) as a predictor of HIV-related outcomes among women and children in a resource-poor setting. DESIGN: We measured serum CRP concentration among 606 HIV-infected women, all of whom were not taking highly-active antiretroviral therapy, 3 to 11 months after they gave birth, and assessed relationships of CRP to HIV-related endpoints, including maternal disease progression, mother-to-child transmission of HIV, and maternal and child mortality. METHODS: We used Cox proportional hazards and regression models adjusted for age, sociodemographic characteristics, anthropometric measurements, hemoglobin, CD4 cell count, HIV viral load, and, for child outcomes, breastfeeding status. RESULTS:Ninety-four women had a high CRP concentration (> 10 mg/l). During the follow-up, 56 women progressed to WHO stage 4 and 188 died, and a high maternal CRP concentration was associated with a 2.26-fold [95% confidence interval (CI), 1.64-3.12] greater risk of progression to stage 4 or death. Among children, 174 acquired HIV and 116 died by age 2 years, and a high maternal CRP concentration was associated with a 3.03-fold (95% CI, 1.85-4.96) greater risk of child mortality. In multivariate analyses among adults, a high maternal CRP concentration was associated with a 1.55-fold (95% CI, 1.08-2.23) greater risk of progression to stage 4 or death. A maternal CRP concentration was not significantly associated with mother-to-child transmission of HIV. CONCLUSIONS: A high maternal CRP concentration independently predicts HIV disease progression, maternal mortality, and child mortality in a resource-poor setting. C-reactive protein may be an important and inexpensive prognostic indicator for HIV-infected women and their children.
RCT Entities:
OBJECTIVE: To evaluate C-reactive protein (CRP) as a predictor of HIV-related outcomes among women and children in a resource-poor setting. DESIGN: We measured serum CRP concentration among 606 HIV-infectedwomen, all of whom were not taking highly-active antiretroviral therapy, 3 to 11 months after they gave birth, and assessed relationships of CRP to HIV-related endpoints, including maternal disease progression, mother-to-child transmission of HIV, and maternal and child mortality. METHODS: We used Cox proportional hazards and regression models adjusted for age, sociodemographic characteristics, anthropometric measurements, hemoglobin, CD4 cell count, HIV viral load, and, for child outcomes, breastfeeding status. RESULTS: Ninety-four women had a high CRP concentration (> 10 mg/l). During the follow-up, 56 women progressed to WHO stage 4 and 188 died, and a high maternal CRP concentration was associated with a 2.26-fold [95% confidence interval (CI), 1.64-3.12] greater risk of progression to stage 4 or death. Among children, 174 acquired HIV and 116 died by age 2 years, and a high maternal CRP concentration was associated with a 3.03-fold (95% CI, 1.85-4.96) greater risk of child mortality. In multivariate analyses among adults, a high maternal CRP concentration was associated with a 1.55-fold (95% CI, 1.08-2.23) greater risk of progression to stage 4 or death. A maternal CRP concentration was not significantly associated with mother-to-child transmission of HIV. CONCLUSIONS: A high maternal CRP concentration independently predicts HIV disease progression, maternal mortality, and child mortality in a resource-poor setting. C-reactive protein may be an important and inexpensive prognostic indicator for HIV-infectedwomen and their children.
Authors: F Roblot; C Godet; G Le Moal; B Garo; M Faouzi Souala; M Dary; L De Gentile; J A Gandji; Y Guimard; C Lacroix; P Roblot; B Becq-Giraudon Journal: Eur J Clin Microbiol Infect Dis Date: 2002-07-13 Impact factor: 3.267
Authors: J Pitt; D Henrard; G FitzGerald; L Mofenson; J Lew; G Hillyer; H Mendez; E Cooper; C Hanson; K C Rich Journal: J Infect Dis Date: 2000-09-08 Impact factor: 5.226
Authors: Bryan Lau; A Richey Sharrett; Larry A Kingsley; Wendy Post; Frank J Palella; Barbara Visscher; Stephen J Gange Journal: Arch Intern Med Date: 2006-01-09
Authors: Wafaie W Fawzi; Gernard I Msamanga; David Hunter; Boris Renjifo; Gretchen Antelman; Heejung Bang; Karim Manji; Saidi Kapiga; Davis Mwakagile; Max Essex; Donna Spiegelman Journal: AIDS Date: 2002-09-27 Impact factor: 4.177
Authors: Grace A McComsey; Douglas Kitch; Paul E Sax; Camlin Tierney; Nasreen C Jahed; Kathleen Melbourne; Belinda Ha; Todd T Brown; Anthony Bloom; Neal Fedarko; Eric S Daar Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Rupak Shivakoti; Erin R Ewald; Nikhil Gupte; Wei-Teng Yang; Cecilia Kanyama; Sandra W Cardoso; Breno Santos; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; Javier R Lama; Umesh Lalloo; Fatima Zulu; Jyoti S Pawar; Cynthia Riviere; Nagalingeswaran Kumarasamy; James Hakim; Richard Pollard; Barbara Detrick; Ashwin Balagopal; David M Asmuth; Richard D Semba; Thomas B Campbell; Jonathan Golub; Amita Gupta Journal: Clin Nutr Date: 2018-05-29 Impact factor: 7.324
Authors: P K Drain; L Mayeza; P Bartman; R Hurtado; P Moodley; S Varghese; G Maartens; G G Alvarez; D Wilson Journal: Int J Tuberc Lung Dis Date: 2014-01 Impact factor: 2.373
Authors: Cecilia M Shikuma; Heather J Ribaudo; Yu Zheng; Roy M Gulick; William A Meyer; Karen T Tashima; Barbara Bastow; Daniel R Kuritzkes; Marshall J Glesby Journal: AIDS Res Hum Retroviruses Date: 2010-11-23 Impact factor: 2.205
Authors: Lelia H Chaisson; Fred C Semitala; Lucy Asege; Sandra Mwebe; Jane Katende; Martha Nakaye; Alfred O Andama; Carina Marquez; Elly Atuhumuza; Moses Kamya; Adithya Cattamanchi; Christina Yoon Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: D H Watts; M Lu; B Thompson; R E Tuomala; W A Meyer; H Mendez; K Rich; C Hanson; P LaRussa; C Diaz; L M Mofenson Journal: Infect Dis Obstet Gynecol Date: 2009-11-02